TxCell hires Lentigen to make vectors used to produce its organ rejection cell therapy

By Gareth Macdonald contact

- Last updated on GMT

iStock/Peshkova
iStock/Peshkova
TxCell SA has hired Lentigen Technology Inc. to make the vectors it uses to make its T-cell transplant rejection therapy.

The deal – financial terms of which were not disclosed – Lentigen make HLA‑A2 CAR lentiviral vector for the production of CAR-Treg transplantation (ENTX#SOT), a cell therapy TxCell is developing with the University of British Columbia.

ENTX#SOT is designed to prevent graft-versus-host disease after transplantation. It was developed using TxCell’s ENTrIA platform which uses chimeric antigen receptors (CARs) to direct antigen-specific regulatory cells (Ag-Tregs) to target autoimmune diseases.

The cell therapy is due to enter first-in-man studies at the end of next year​.

Lentigen – which is owned by Miltenyi Biotec GmbH​ – will make HLA-A2 CAR lentiviral vectors batches for the trials. It will also make vectors for planned preclinical studies.

TxCell is looking for a second contract manufacturing organisation (CMO) to use the vectors to produce ENTX#SOT.

The French biotechnology firm said it is developing a manufacturing process for CAR‑Treg cells and expects to start the technology transfer to the selected CMO by the end of the year.

TxCell has previously announced deals with Belgian CMO MaSTherCell​ and US contractor PCT​, a subsidiary of Caladrius Biosciences, both of which focused on the manufacture of its – which made the T-cell Crohn’s disease therapy, Ovasave.

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Related suppliers

Follow us

Products

View more

Webinars